AI-Based Detection and Scoring of TROP2 Expression in IHC-Stained NSCLC Specimens Read more about AI-Based Detection and Scoring of TROP2 Expression in IHC-Stained NSCLC Specimens
Identification of molecular alterations in soft tissue sarcoma patients with combined pan-cancer CGP and bespoke sarcoma fusion detection testing Read more about Identification of molecular alterations in soft tissue sarcoma patients with combined pan-cancer CGP and bespoke sarcoma fusion detection testing
PaletrraTM AI: Automated phenotyping of multiplex immunofluorescence datasets via information maximizing self-training Read more about PaletrraTM AI: Automated phenotyping of multiplex immunofluorescence datasets via information maximizing self-training
Antibody-Drug Conjugate Immuno-Oncology Panel for Comprehensive Characterization of the Tumor and Associated Microenvironment Read more about Antibody-Drug Conjugate Immuno-Oncology Panel for Comprehensive Characterization of the Tumor and Associated Microenvironment
Bridging HER2 Testing and Treatment: Real-World Evidence Across 22 Solid Tumors Read more about Bridging HER2 Testing and Treatment: Real-World Evidence Across 22 Solid Tumors
Bridging the Gap Between Clinical Utility and Coverage: Real-World Impact of Unreimbursed NGS Testing Read more about Bridging the Gap Between Clinical Utility and Coverage: Real-World Impact of Unreimbursed NGS Testing
From Infancy to Young Adulthood: Exploring the Divergent Genomic Mechanisms that Drive AML Read more about From Infancy to Young Adulthood: Exploring the Divergent Genomic Mechanisms that Drive AML
Homologous Recombination Deficiency (HRD) and Folate Receptor Alpha (FOLR1) in Ovarian Cancer Read more about Homologous Recombination Deficiency (HRD) and Folate Receptor Alpha (FOLR1) in Ovarian Cancer
Circulating tumor DNA and late recurrence in high-risk, hormone receptor-positive, HER2-negative breast cancer: An updated analysis of the CHiRP study Read more about Circulating tumor DNA and late recurrence in high-risk, hormone receptor-positive, HER2-negative breast cancer: An updated analysis of the CHiRP study